Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maravai Lifesciences Holdings (MRVI) Cash & Equivalents: 2022-2025

Historic Cash & Equivalents for Maravai Lifesciences Holdings (MRVI) over the last 3 years, with Sep 2025 value amounting to $243.6 million.

  • Maravai Lifesciences Holdings' Cash & Equivalents fell 57.87% to $243.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $243.6 million, marking a year-over-year decrease of 57.87%. This contributed to the annual value of $322.4 million for FY2024, which is 43.93% down from last year.
  • According to the latest figures from Q3 2025, Maravai Lifesciences Holdings' Cash & Equivalents is $243.6 million, which was down 9.76% from $269.9 million recorded in Q2 2025.
  • In the past 5 years, Maravai Lifesciences Holdings' Cash & Equivalents registered a high of $632.1 million during Q4 2022, and its lowest value of $243.6 million during Q3 2025.
  • Its 3-year average for Cash & Equivalents is $456.9 million, with a median of $567.4 million in 2024.
  • Data for Maravai Lifesciences Holdings' Cash & Equivalents shows a maximum YoY plummeted of 57.87% (in 2025) over the last 5 years.
  • Maravai Lifesciences Holdings' Cash & Equivalents (Quarterly) stood at $632.1 million in 2022, then dropped by 9.04% to $575.0 million in 2023, then crashed by 43.93% to $322.4 million in 2024, then plummeted by 57.87% to $243.6 million in 2025.
  • Its Cash & Equivalents was $243.6 million in Q3 2025, compared to $269.9 million in Q2 2025 and $285.1 million in Q1 2025.